CoChat

Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial

Open access
Eskesen, Dorte, Jespersen, Lillian, Michelsen, Birgit, Whorwell, Peter J., Müller-Lissner, Stefan, Morberg, Cathrine M. · 2015 · British Journal of Nutrition

The DOI matches its Crossref record, with a small difference in title or year; 49 of the 57 references it cites were found in a registry or an index; 16 of the 43 sources its claims cite were checked for support.

Abstract

The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points - defecation frequency and gastrointestinal (GI) well-being - in healthy adults with low defecation frequency and abdominal discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of abdominal discomfort and symptoms. GI well-being, defined as global relief of abdominal discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50% of the time was 1·31 (95% CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95% CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P<0·05). Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose. Overall, 4 weeks' supplementation with the probiotic strain BB-12® resulted in a clinically relevant benefit on defecation frequency. The results suggest that consumption of BB-12® improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).

Overview

CoChat Summary

TL;DR

In a large randomised, double-blind, placebo-controlled trial, 4 weeks of *Bifidobacterium animalis* subsp. *lactis* BB-12® improved defecation frequency in healthy adults with low defecation frequency and abdominal discomfort, but did not significantly improve global GI well-being. The 1 and 10 billion CFU/d doses performed similarly, suggesting a ceiling effect at the lower dose.

Key findings

  • For the initial defecation-frequency responder definition (above baseline for ≥50% of the time), the overall OR was 1·31 (95% CI 0·98, 1·75), P=0·071; the per-protocol analysis showed significant effects in the 1 billion group and overall (OR 1·52 and 1·43, respectively).
  • With tightened responder criteria (increase of ≥1 d/week for ≥50% of the time), the overall OR was 1·55 (95% CI 1·22, 1·96), P=0·0003, with ORs between 1·50 and 1·61 for each dose and treatment overall.
  • Average defecation frequency increased in all groups, with a significant overall probiotic treatment effect (P=0·0065) and significantly higher frequency versus placebo at all weeks for probiotic treatment overall (all P<0·05); change from baseline was 1·54, 1·30 and 1·15 d/week for 1 billion, 10 billion and placebo, respectively.
  • GI well-being (global relief of abdominal discomfort) showed no statistically significant differences; abdominal pain and bloating decreased in all groups without treatment differences.

Methods

  • Randomised, double-blind, placebo-controlled, parallel-group trial at eight centres in France, Germany and the UK between September 2010 and December 2012, with a 2-week run-in and 4-week intervention.
  • 1248 healthy men and women aged 18–70 years with low defecation frequency (2–4 d/week) and general abdominal discomfort were randomised to 1 or 10 billion CFU/d BB-12® or matching placebo once daily; the planned sample size was 1740, but interim analyses closed the 1 billion arm after the first interim analysis and the 10 billion arm after the second.
  • Primary end points were responder rates for defecation frequency and GI well-being, analysed in the intention-to-treat population using logistic regression; supportive analyses included per-protocol, GEE models for average defecation frequency, predefined subgroup analyses, and post hoc tightened responder criteria.

Limitations

  • The paper states that very high placebo response rates were observed, that the initial responder definition may have been too easy to reach, and that the global assessment of GI well-being has been debated as an end point.
  • The paper states that intention-to-treat analysis introduces heterogeneity by combining compliant and non-compliant subjects, that regression towards the mean may have underestimated the true probiotic effect, and that mechanisms and dose–response reasons remain unknown.
  • Evident from the text: the dose arms were stopped at different interim analyses, resulting in unequal group sizes; the study population had mild symptoms not severe enough to consult a doctor, so generalisability to IBS or clinically constipated populations is uncertain.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1017/s0007114515003347

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Consort flow chart. CFU, colony-forming units; ITT, intention-to-treat; PD, protocol deviations; PP, per-protocol.
Fig. 1 Consort flow chart. CFU, colony-forming units; ITT, intention-to-treat; PD, protocol deviations; PP, per-protocol.CC BY · PubMed Central
Fig. 2 Responders for defecation frequency (intention-to-treat (ITT) and per-protocol (PP) analysis). A responder was defined as a subject with a weekly defecation frequency above baseline for at least 50 % of the time – that is, for at least 2 of the 4-week treatment period; due to missing data, six subjects (0·5 %) could not be classified as responders or non-responders. CFU, colony-forming units; OR, OR for being a responder. * Number of subjects (% responders).
Fig. 2 Responders for defecation frequency (intention-to-treat (ITT) and per-protocol (PP) analysis). A responder was defined as a subject with a weekly defecation frequency above baseline for at least 50 % of the time – that is, for at least 2 of the 4-week treatment period; due to missing data, six subjects (0·5 %) could not be classified as responders or non-responders. CFU, colony-forming units; OR, OR for being a responder. * Number of subjects (% responders).CC BY · PubMed Central
Fig. 3 Responders for defecation frequency with tightened responder criteria (intention-to-treat (ITT) analysis). A responder was defined as a subject with a weekly defecation frequency ≥1 d/week above baseline for at least 50 % of the time – that is, for at least 2 of the 4-week treatment period; due to missing data, six subjects (0·5 %) could not be classified as responders or non-responders. CFU, colony-forming units; OR, OR for being a responder. * Number of subjects (% responders).
Fig. 3 Responders for defecation frequency with tightened responder criteria (intention-to-treat (ITT) analysis). A responder was defined as a subject with a weekly defecation frequency ≥1 d/week above baseline for at least 50 % of the time – that is, for at least 2 of the 4-week treatment period; due to missing data, six subjects (0·5 %) could not be classified as responders or non-responders. CFU, colony-forming units; OR, OR for being a responder. * Number of subjects (% responders).CC BY · PubMed Central
Fig. 4 Weekly changes from baseline in defecation frequency (intention-to-treat population). Values are means with their standard errors. Defecation frequency recorded in subject diaries and reported as days per week with defecation. Overall treatment effect (P=0·0054). The one billion group is significantly different from the placebo group at weeks 2, 3 and 4 (** P<0·01). The ten billion group is significantly different from the placebo group at weeks 1 and 2 (* P<0·05). CFU, colony-forming units. , 1 billion CFU, n 343; , 10 billion CFU, n 452; , placebo, n 453.
Fig. 4 Weekly changes from baseline in defecation frequency (intention-to-treat population). Values are means with their standard errors. Defecation frequency recorded in subject diaries and reported as days per week with defecation. Overall treatment effect (P=0·0054). The one billion group is significantly different from the placebo group at weeks 2, 3 and 4 (** P<0·01). The ten billion group is significantly different from the placebo group at weeks 1 and 2 (* P<0·05). CFU, colony-forming units. , 1 billion CFU, n 343; , 10 billion CFU, n 452; , placebo, n 453.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 1 Not valid · 7 Not checked · 99 Own results and interpretations

42 more claims

Create a free account to see all 118 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 59
  • It may state two separate claims as one. 34
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. Uchida, 2005, Effect of fermented milk containing Bifidobacterium lactis Bb-12 on stool frequency, defecation, fecal microbiota and safety of excessive ingestion in healthy female students – 2nd report, J Nutr Food, 8, 39

Cited by

See all 78

Metadata

Authors
Eskesen, D., Jespersen, L., Michelsen, B., Whorwell, P. J., Müller-Lissner, S., & Morberg, C. M.
Affiliations
  • Chr. Hansen (Denmark) (DK)
  • Park-Klinik Weißensee (DE)
Corresponding author
Eskesen, Dorte
Venue
British Journal of Nutrition
Published
2015-09-18
Volume
114
Issue
10
Pages
1638-1646
ISSN
  • 0007-1145 (ISSN-L)
  • 1475-2662
OpenAlex
W2136311124
Cited by
78
References
57
Citations by year
2026: 7 · 2025: 8 · 2024: 3 · 2023: 6 · 2022: 13 · 2021: 8 · 2020: 5 · 2019: 8 · 2018: 7 · 2017: 10 · 2016: 3
FWCI
6.70
Type
journal article
Language
en
Open access
Locations
  • British Journal Of Nutrition (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, cc-by)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
Bifidobacterium animalis subsp. lactis BB-12, probiotics, stool frequency, abdominal discomfort, constipation, healthy adults, dose-response relationship, ceiling effect
MeSH terms
Adult, Bifidobacterium, Defecation, Double-Blind Method, Female, France, Germany, United Kingdom, Humans, Male, Middle Aged, Patient Compliance, Placebos, Surveys and Questionnaires, Time Factors, Abdominal Pain, Odds Ratio, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. https://app.cochat.ai/papers/10.1017/s0007114515003347
The paper
Eskesen, D., Jespersen, L., Michelsen, B., Whorwell, P. J., Müller-Lissner, S., & Morberg, C. M. (2015). Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. British Journal of Nutrition. https://doi.org/10.1017/s0007114515003347

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.